How will you select patients with brain metastases for TTFields?

The METIS study included only NSCLC patients and found a greater impact for patients previously treated with ICI. How does this impact your patient selection?

This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by the Plenary Session Presentation "Tumor Treating Fields (TTFields) After Stereotactic Radiosurgery (SRS) for Brain Metastases from Non-Small Cell Lung Cancer (NSCLC BM): Final Results of The Phase 3 METIS Trial" by Dr. @Vinai Gondi.

Answer from: Radiation Oncologist at Academic Institution

The METIS trial restricted eligibility only to patients with brain metastases from non-small cell lung cancer. Therefore, we would not be able to extrapolate these results and data to other tumor types and histologies. Indeed, a post hoc analysis of the data did demonstrate a greater impact in patie...

Comments

Radiation Oncologist at Saint John Macomb-Oakland Hospital
IMHO, ASTRO has jumped the shark on this one: "Ti...

Radiation Oncologist at UCLA | VA Greater Los Angeles Healthcare System
Transparency FTW.

Answer from: Radiation Oncologist at Community Practice

I congratulate the authors on a well-designed and conducted trial asking an important question. I currently offer TTF to my GBM patients, and some choose to use it. I would like to see a cost-effectiveness analysis of TTF in this setting. Time to neurocognitive failure, OS, and radiological respons...

Please select the option that best describes you:

How will you select patients with brain metastases for TTFields?

Related Questions